BRISTOL MYERS SQUIBB

🇫🇷France

Country: 🇫🇷France

Ownership: -

Established: 1989-01-01

Employees: 30K

Market Cap: $97.5B

Website: https://www.bms.com/

Clinical Trials

A Study of Mezigdomide in Healthy Participants and Participants With Hepatic Impairment

Phase 1

Completed

Conditions: Hepatic Impairment

Interventions: Drug: Mezigdomide

First Posted Date: 2023-01-31

Last Posted Date: 2024-02-07

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 32

Registration Number: NCT05707390

Locations: 🇺🇸
Orlando Clinical Research Center OCRC, Orlando, Florida, United States
🇺🇸
The Texas Liver Institute, San Antonio, Texas, United States
🇺🇸
PANAX, Miami Lakes, Florida, United States

A Study to Evaluate the Effect of Deucravacitinib on Quality of Life in Participants With Plaque Psoriasis in a Community Setting

Phase 4

Active, not recruiting

Conditions: Psoriasis

Interventions: Drug: Deucravacitinib
Other: Placebo

First Posted Date: 2023-01-27

Last Posted Date: 2024-10-23

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 180

Registration Number: NCT05701995

Locations: 🇺🇸
Local Institution - 0006, Phoenix, Arizona, United States
🇺🇸
Local Institution - 0034, Scottsdale, Arizona, United States
🇺🇸
Local Institution - 0015, North Little Rock, Arkansas, United States

and more 35 locations

A Rollover Study of CC-122

Phase 1

Active, not recruiting

Conditions: Non-Hodgkin Lymphoma

Interventions: Drug: CC-122
Drug: Dexamethasone

First Posted Date: 2023-01-18

Last Posted Date: 2024-01-08

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 12

Registration Number: NCT05688475

Locations: 🇳🇱
Local Institution - 400, Amsterdam, Netherlands
🇯🇵
Local Institution - 500, Koto-ku, Tokyo, Japan
🇺🇸
Local Institution - 100, New York, New York, United States

and more 4 locations

A Study to Evaluate the Absorption, Metabolism, and Excretion (ADME) of BMS-986435

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: MYK-224

First Posted Date: 2023-01-17

Last Posted Date: 2023-05-25

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 7

Registration Number: NCT05686096

Locations: 🇺🇸
Local Institution - 0001, Madison, Wisconsin, United States

A Study Investigating the Safety, Tolerability, Drug Levels and Drug Effect of BMS-986278 in Healthy Adult Participants (Part 1) and Japanese Participants (Part 2)

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: BMS-986278
Drug: Placebo
Drug: Sildenafil

First Posted Date: 2023-01-13

Last Posted Date: 2023-08-24

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 61

Registration Number: NCT05684289

Locations: 🇺🇸
Syneos Health Clinical Research Services, Llc, Miami, Florida, United States
🇺🇸
Altasciences Clinical Los Angeles, Inc, Cypress, California, United States

A Study of Absorption, Metabolism, and Elimination CC-90010 in Participants With Advanced Solid Tumors

Phase 1

Withdrawn

Conditions: Advanced Solid Tumors

Interventions: Drug: [14C]CC-90010
Drug: CC-90010

First Posted Date: 2023-01-10

Last Posted Date: 2024-04-17

Lead Sponsor: Bristol-Myers Squibb

Registration Number: NCT05678283

Locations: 🇪🇸
Local Institution - 0002, Madrid, M, Spain

A Study to Assess Real-World Patient-Reported Outcomes With Fedratinib for Myelofibrosis Post-Ruxolitinib

Recruiting

Conditions: Myelofibrosis

First Posted Date: 2022-12-27

Last Posted Date: 2022-12-27

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 50

Registration Number: NCT05665192

Locations: 🇦🇹
Local Institution, City, State, Austria

A Study to Determine the Efficacy and Safety of Luspatercept in Adult Participants and to Evaluate the Safety and Pharmacokinetics in and Adolescent Participants With Alpha (α)-Thalassemia

Phase 2

Recruiting

Conditions: Anemia

Interventions: Biological: Luspatercept
Drug: Placebo

First Posted Date: 2022-12-27

Last Posted Date: 2024-12-17

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 249

Registration Number: NCT05664737

Locations: 🇬🇷
Local Institution - 0007, Larissa, E, Greece
🇬🇷
Local Institution - 0006, Athens, Greece
🇬🇷
Local Institution - 0009, Goudi, Greece

and more 33 locations

A Study to Describe the Switching From a First- or Second-line Disease Modifying Therapy (DMT) to Ozanimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)

Recruiting

Conditions: Multiple Sclerosis, Relapsing-Remitting

First Posted Date: 2022-12-21

Last Posted Date: 2024-01-11

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 180

Registration Number: NCT05658601

Locations: 🇮🇹
Neuromed Istituto Neurologico Mediterraneo, Isernia, Italy

A Study to Assess the Effects on the Single-Dose Drug Levels of Mavacamten in Healthy Participants

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: Mavacamten Capsule 1
Drug: Mavacamten Capsule 2
Drug: Mavacamten Capsule 3

First Posted Date: 2022-12-20

Last Posted Date: 2023-10-11

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 95

Registration Number: NCT05658146

Locations: 🇺🇸
Local Institution - 0001, Anaheim, California, United States
🇺🇸
Local Institution - 0002, Miami, Florida, United States
🇺🇸
Local Institution - 0003, Springfield, Missouri, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy